Division of Medical Oncology and Hematology, Loma Linda University, Loma Linda, CA 92354, USA.
J Hematol Oncol. 2010 May 2;3:18. doi: 10.1186/1756-8722-3-18.
We have reviewed the pivotal presentations in non-small cell lung cancer (NSCLC) from the 2009 annual meeting of the American Society of Clinical Oncology. We have discussed the scientific data, the impact on standards of care, and ongoing clinical trials.In patients with early-stage NSCLC, there is still no data to support the superiority of either neoadjuvant or adjuvant chemotherapy. However, adjuvant cisplatin-based chemotherapy has sustained the survival benefits after median follow-up of more than 9 years. The first-line treatment with inhibitors of epidermal growth factor receptor (EGFR) could be considered for the treatment of EGFR mutated patients with metastatic disease.Several maintenance studies with cytotoxic or biological agents have also demonstrated promising outcomes. Finally, novel targeted agents such as inhibitors of histone deacetylase and multi-targeted tyrosine kinase inhibitor have shown promising activity in NSCLC treatment.
我们回顾了 2009 年美国临床肿瘤学会年会上关于非小细胞肺癌（NSCLC）的重要演讲。我们讨论了科学数据、对护理标准的影响以及正在进行的临床试验。在早期 NSCLC 患者中，仍然没有数据支持新辅助化疗或辅助化疗的优越性。然而，基于顺铂的辅助化疗在中位随访超过 9 年后仍保持生存获益。对于转移性疾病的 EGFR 突变患者，可考虑使用表皮生长因子受体（EGFR）抑制剂作为一线治疗。几项细胞毒性或生物制剂的维持研究也显示出有前景的结果。最后，新型靶向药物，如组蛋白去乙酰化酶抑制剂和多靶点酪氨酸激酶抑制剂，在 NSCLC 治疗中显示出有希望的活性。
